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poly(ADP-ribose) polymerase in the rat hip-
pocampus may contribute to cellular recovery
following sublethal transient global ischemia.
J Neurochem. 2000;74:1636-45.
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Reply to the Editor:
In response to the comments of Bloch and
Mehlhorn on the effects of poly–adenosine
diphosphate–ribose polymerase (PARP) in-
hibition after cardioplegic arrest and reper-
fusion, we agree that the PARP enzyme
family has a complex regulatory role under
several physiologic and pathologic condi-
tions. After a decade of intensive research,
we reported on the role of PARP in gener-
al1 and focusing on ischemia-reperfusion
injury.2,3 To date, the role of PARP in
physiologic DNA repair, apoptosis, and ne-
crosis can be summarized as follows: de-
pending on the severity of DNA damage,
genotoxic stimuli can trigger three different
pathways. In the case of mild DNA dam-
age, PARP facilitates DNA repair and thus
survival. However, the exact physiologic
role of PARP still remains to be clarified;
many authors have suggested that PARP is
an abundant enzyme with limited role un-
der physiologic conditions. More severe
DNA damage induces apoptotic cell death,
during which caspases, the main executor
enzymes of apoptotic process, inactivate
PARP, cleaving it into two fragments (p89
and p24) and thus PARP cleavage by
caspases is a marker of apoptotic cell
death. This pathway allows cells with ir-
reparable DNA damage to become elimi-
nated in a safe way. Much of the cell death
related literature focuses on PARP cleav-
age (as opposed to PARP activation). The
most severe DNA damage may cause ex-
cessive PARP activation, depleting oxi-
dized nicotinamide adenine dinucleotide
(NAD) and adenosine triphosphate stores.
NAD/ATP depletion blocks apoptosis
and results in necrosis. This pathway,
which we proposed in the article under
discussion, has no relationship to the PARP
cleavage pathway. As mentioned previ-
ously, the cleaved form of PARP is cata-
lytically inactive; PARP cleavage has been
considered as an endogenous mechanism
that serves to prevent PARP-dependent
metabolic suppression and necrosis.
Considering the previously mentioned
mechanisms, the cited study of Fischer and
colleagues4 is not contrary to but support-
ive of our results. They found caspase ac-
tivation but no apoptotic cell death and no
PARP cleavage in a similar model of car-
diopulmonary bypass and cardiac arrest.
On the basis of these findings, Bloch and
Mehlhorn criticized our study, suggesting
that pharmacologic PARP inhibition may
be detrimental by inhibiting physiologic
DNA repair and promoting apoptosis.
We do believe that the fact they did not
find apoptotic cell death and PARP cleav-
age (inactivated PARP) after cardioplegic
arrest indicates that the primary form of
cell damage is the necrotic (or prenecrotic)
pathway, with concomitant PARP activa-
tion instead of PARP cleavage. It is also
evident that cardioplegic arrest leads to
adenosine triphosphate depletion, and
therefore it is not surprising that no or
negligible apoptosis occurs during reperfu-
sion, because apoptosis is an adenosine
triphosphate–dependent process. The loss
of the ability of the cells to undergo apo-
ptosis results in missing PARP cleavage
and turns the cells toward PARP activation
and metabolic suppression. Indeed, there is
immunohistochemical evidence of PARP
activation in different models of cardiople-
gic arrest and reperfusion.2,5 It is also im-
portant to note that cellular PARP activa-
tion does not always need to culminate in
full-fledged cellular necrosis (complete
breakdown of cell membrane integrity and
release of cellular content into the extracel-
lular space); a partial, and reversible sup-
pression of cellular energetic pools can be
associated with reversible cell dysfunction.
These phenomena are sometimes termed
prenecrosis or cytopathic hypoxia and are
reversible by PARP inhibition.6,7
The questions raised about additional
functions of PARP, its potential toxicity,
and its role in aging were far beyond the
scope of our study; however, we refer to a
previous review article in which they were
discussed and considered in detail.1 We
note, nevertheless, that in addition to par-
ticipating in the NAD depletion/prenecro-
sis/necrosis pathway PARP activity plays
an active role in the transcription of various
proinflammatory genes. Suppression of this
process thus may provide additional car-
dioprotective benefits during and after car-
dioplegia.
The reference made by Bloch and
Mehlhorn to stroke and NAD depletion
does not have any direct relationship to our
current work, but for the record we note
that the vast majority of studies (more than
20 published reports, reviewed in Vira´g
and Szabo´1) demonstrate the marked pro-
tective effect of PARP inhibitors and ge-
netic PARP deficiency in various models of
stroke. In most experimental models of
stroke (similar to myocardial ischemia) a
prenecrotic/necrotic pathway of cell death
(as opposed to apoptosis or PARP cleav-
age) appears to play the dominant role and
can be beneficially affected by PARP inhi-
bition.
Whether inhibition or scavenging of up-
stream effectors of apoptosis or necrosis,
such as reactive oxygen species, would be
more effective by reduction of endogenous
PARP activation in addition to the inhibi-
tion of DNA damage and subsequent cell
death remains to be clarified. We have pre-
clinical experience with the novel porphy-
rinic peroxynitrite decomposition catalyst
FP15,8,9 which shows beneficial effects
during regional ischemia/reperfusion8,9
and after cardioplegic arrest (unpublished
observations).
In conclusion, we maintain that PARP
inhibition is a promising concept for reduc-
ing cell damage during ischemia and reper-
fusion. Even if alternative cardiac surgical
techniques such as beating-heart surgery
minimize ischemia-reperfusion injury,
PARP inhibition may improve postopera-
tive outcome in those cases in which car-
dioplegia is still necessary.
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Interventional atrial incision in the
Fontan operation: Novel prophylaxis
or iatrogenic substrate for intra-
atrial reentrant tachycardia?
To the Editor:
In the March 2004 issue of the Journal,
Collins and colleagues1 published short-
term results of their interesting prospective,
randomized, blinded trial to assess the fea-
sibility, safety, and efficacy of an interven-
tional atrial incision placed at the time of
the Fontan operation to reduce the devel-
opment of intra-atrial reentrant tachycardia
(IART). Although the idea sounds clever,
there are serious concerns about the long-
term efficacy of their modification.
Staged palliation culminating in a suc-
cessful Fontan procedure is the current
surgical goal for most patients with a func-
tional single ventricle. Since its introduc-
tion in 1968, the Fontan procedure has un-
dergone many modifications.2 At present,
two modifications in common use are the
lateral tunnel and extracardiac conduit.3
The incidence of late supraventricular
tachycardia after a lateral tunnel procedure
varies from 0% to 22%, and that after an
extracardiac conduit operation varies from
0% to 8%.3 These figures definitely do not
justify undertaking a prophylactic proce-
dure for IART in all patients who undergo
Fontan operation in the modern era. It is
extremely difficult to predict with accuracy
the patients who will definitely have IART.
An even more important concern is the
high incidence of early sinus node dysfunc-
tion among the study patients. Early sinus
node dysfunction may carry long-term im-
plications because it predicts late sinus
node dysfunction,4 which in turn is associ-
ated with late supraventricular tachycar-
dia.5 Although Collins and colleagues1 at-
tributed this high incidence to a “broad
definition” of sinus node dysfunction, I
think that the interventional atrial incision
may be partially if not wholly responsible
for this phenomenon. There is a consensus
of opinion that the presence of a region of
structural or functional block within the
atria is a substrate for atrial muscle reen-
try.5 The Fontan operation results in re-
gions of structural block as a result of atrial
incisions and multiple suture lines, as well
as functional block from relative right atrial
hypertension with right atrial dilation and
hypertrophy.5 The “prophylactic atrial in-
cision” not only will act as region of struc-
tural block in the long term but probably
interferes with the blood supply of the si-
nus node in the short term. This could well
explain the high incidence of early sinus
node dysfunction in the study.
In conclusion, the high prevalence of
atrial arrhythmias is a result of extensive
atrial surgical procedures, elevated atrial
pressures, and atrial enlargement. Until
modifications aimed at avoiding atrial ma-
nipulation are discovered, earlier identifi-
cation of sinus node dysfunction with early
institution of atrial pacing may be the best
prophylaxis to decrease the incidence of
IART in this group of patients. My mes-
sage for Collins and colleagues in particu-
lar and readers in general is that any “pro-
phylactic atrial incision” made with the
best of intentions will act as nothing but a
substrate for IART.
Shahzad G. Raja, MRCS
Department of Paediatric Cardiac Surgery
Alder Hey Hospital
Eaton Rd
Liverpool L12 2AP, United Kingdom
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Reply to the Editor:
The Fontan population is heterogeneous in
terms of the underlying anatomy and num-
ber and nature of surgical interventions be-
fore the Fontan operation. Many factors are
thought to be associated with the develop-
ment of atrial arrhythmias in this group.
Animal studies have suggested that surgi-
cal incision and extended suture lines are
particularly likely to create an arrhythmo-
genic substrate.1-3 The more recent ver-
sions of the Fontan procedure (lateral tun-
nel or the extracardiac conduit) have had
lower reported incidences of late atrial ar-
rhythmias than the older types of Fontan
operations.4 Long-term follow-up of the
extracardiac conduit Fontan operation has
not yet been reported with respect to ar-
rhythmia, but Stamm and colleagues4 have
recently shown that the lower incidence of
atrial tachycardia in the lateral tunnel Fon-
tan procedure persisted through a mean 10-
year follow-up.4 One can interpret this
finding to mean that the current Fontan
techniques are in fact less arrhythmogenic
then was initially projected when our study
was undertaken. If so, placement of an in-
terventional atrial incision to the lateral
tunnel Fontan may not be warranted in
every case, only for patients deemed at
higher risk (eg, with a preoperative history
of atrial tachycardia).
Although avoiding atrial manipulation
and suture lines altogether has theoretic
benefits, it is not practical in all cases. If
atrial suture lines are required for the sur-
gical intervention, then choosing to place
or extend them in such a way to reduce the
likelihood of atrial arrhythmias is war-
ranted. Our interventional atrial incision to
the lateral tunnel Fontan procedure was
designed to transect potential arrhythmia
circuits around the atriotomy or the right
atrioventricular valve, the primary areas
where atrial arrhythmias typically develop.
It was designed to be simple, to be feasible
in patients with varied anatomy, and to
have low added risks for the patient. The
location of the incision is inferior to the
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